Evidence map›Paper›PMID 40324993›Full record

ArticleCell death discovery2025

Mitochondrial reactive oxygen species promote cancer metastasis and tumor microenvironment immunosuppression through gasdermin D.

Naijun Miao, Zhengchun Kang, Zhuning Wang, Wenyan Yu, Ting Liu, Ling-Zhijie Kong, Ying Zheng, Changli Ding, Zhiyong Zhang, Chen Zhong and 2 more

Abstract read
In one paragraph

Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Role of pyroptosis in melanoma: Molecular mechanisms and therapeutic potentials.Apoptosis : an international journal on programmed cell death · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. SodA promotes immune evasion ofMicrobiology spectrum · 2026
    Article
  10. Review
  11. The Roles of ProteinCancer communications (London, England) · 2026
    Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Naijun Miao *Department of Oncology, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, 200434, China.
Zhengchun Kang *Department of Colorectal Surgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Zhuning Wang *Center for Immune-related Diseases at Shanghai Institute of Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Wenyan Yu *Department of Oncology, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, 200434, China.
Ting LiuDepartment of Anesthesiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Ling-Zhijie KongDepartment of Oncology, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, 200434, China.
Ying ZhengDepartment of Oncology, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, 200434, China.
Changli DingDepartment of Oncology, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, 200434, China.
Zhiyong ZhangDepartment of Oncology, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, 200434, China.
Chen ZhongDepartment of Medical Oncology, The 960th Hospital of the PLA Joint Logistice Support Force, Jinan, 250031, Shandong, China. zhongchen0504@sina.com.
Qingliang FangDepartment of Radiation Oncology, LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. fangqingliang@shutcm.edu.cn.
Kaichun LiDepartment of Oncology, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, 200434, China. likaichun@tongji.edu.cn.ORCID http://orcid.org/0000-0001-6442-4388

Funding

Ministry of Health of China | Wu Jieping Medical Foundation No. 320.6750.2020-18-2Shanghai Municipal Education Commission | E-Institutes of Shanghai Municipal Education Commission 21CGA19
6 · The paper itself

Abstract

Although recent research has established that gasdermin D (GSDMD), a factor that drives pyroptosis, is essential for cell death and inflammation, its involvement in cancer metastasis has yet to be elucidated. In this study, GSDMD was significantly increased in lung neutrophils at the metastatic stage from a murine orthotropic 4T1 breast cancer model. Moreover, the N terminal domain from cleaved GSDMD exhibited a positive correlation with increased mitochondrial reactive oxygen species (mROS) and serum high mobility group box 1 (HMGB-1) levels. Mechanistically, mROS inhibition significantly suppressed GSDMD-N oligomerization and pore formation. In addition, the activation of GSDMD significantly enhanced the formation of neutrophil extracellular traps (NETs) following treatment with Cathepsin C. Within a murine orthotopic breast cancer model using 4T1 cell line, the inhibition of GSDMD through the application of LDC7559 significantly attenuated the metastatic spread of breast cancer to the lung. In addition, knockout of GSDMD reduced lung metastasis in E0771 intravenous injection murine model. Furthermore, inhibition of GSDMD reduced the number of myeloid derived suppressor cells (MDSC) in the metastatic lung of breast cancer mouse model, while concurrently increasing both the percentage and total cell count of CD8

Identifiers

PMID40324993
PMCPMC12053750

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.